Magenta therapeutics inc - made strategic decision to discontinue enrollment in phase 2 study of mgta-456 in inherited metabolic disorders
Magenta therapeutics provides portfolio update: stem cell mobilization and conditioning programs prioritized and advancing toward clinical milestones.magenta therapeutics inc - mgta-145 first-line mobilization program to move into phase 2 studies in autologous and allogeneic patients in 2020.magenta therapeutics inc - mgta-117 antibody-drug conjugate (adc)-based conditioning program on track for initial clinical data in 2021.magenta therapeutics inc - made strategic decision to discontinue enrollment in phase 2 study of mgta-456 in inherited metabolic disorders.magenta therapeutics inc - enrollment in phase 2 investigator-initiated trial in patients with blood cancers is expected to be completed.magenta therapeutics inc - to discontinue enrollment in phase 2 study in imds due to enrollment challenges, particularly during covid-19 pandemic.magenta therapeutics - to discontinue enrollment in phase 2 study in imds, due to challenges of allogeneic stem cell transplant in imds patients.magenta therapeutics - to discontinue enrollment in phase 2 study in imds, also due to feedback from fda on endpoints and clinical trial design.
DNTH Ratings Summary
DNTH Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission